Research programme: PI3K and MAPK inhibitors - AEterna Zentaris

Drug Profile

Research programme: PI3K and MAPK inhibitors - AEterna Zentaris

Alternative Names: AEZS-126; AEZS-129; AEZS-129-136; AEZS-131; AEZS-132; AEZS-134; AEZS-136; AEZS-136 PI3K/Erk dual inhibitor - Aeterna Zentaris; AEZS-140; D-106669; D-87503

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AEterna Zentaris Inc
  • Class 2 ring heterocyclic compounds; Pyrazines; Pyridines; Pyridones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Germany (PO)
  • 04 Aug 2015 AEZS-140 and back-up compounds are available for licensing as of 29 Jul 2015. http://www.aezsinc.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top